These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39157636)

  • 1. A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV.
    Beran C; Duggan JM; Sahloff EG
    J Pharm Technol; 2024 Aug; 40(4):194-201. PubMed ID: 39157636
    [No Abstract]   [Full Text] [Related]  

  • 2. US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance.
    Vardanega V; New E; Mezzio D; Eddowes LA
    J Manag Care Spec Pharm; 2024 Sep; 30(9):1001-1012. PubMed ID: 39213144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus.
    Chatzidaki I; Curteis T; Luedke H; Mezzio DJ; Rhee MS; McArthur E; Eddowes LA
    Value Health; 2023 Jun; 26(6):810-822. PubMed ID: 36566886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.
    Anderson SJ; van Doornewaard A; Turner M; Jacob I; Clark A; Browning D; Schroeder M
    Clin Ther; 2022 Jun; 44(6):886-900. PubMed ID: 35610081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.
    Tailor MW; Chahine EB; Koren D; Sherman EM
    Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
    Margot NA; Naik V; VanderVeen L; Anoshchenko O; Singh R; Dvory-Sobol H; Rhee MS; Callebaut C
    J Infect Dis; 2022 Nov; 226(11):1985-1991. PubMed ID: 36082606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):360-382. PubMed ID: 38853601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):354-359. PubMed ID: 38853605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.
    Margot N; Pennetzdorfer N; Naik V; Rhee M; Callebaut C
    Antivir Ther; 2023 Dec; 28(6):13596535231220754. PubMed ID: 38085652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.
    Muccini C; Canetti D; Castagna A; Spagnuolo V
    Drug Des Devel Ther; 2022; 16():297-304. PubMed ID: 35115764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
    Aberg JA; Shepherd B; Wang M; Madruga JV; Mendo Urbina F; Katlama C; Schrader S; Eron JJ; Kumar PN; Sprinz E; Gartland M; Chabria S; Clark A; Pierce A; Lataillade M; Tenorio AR
    Infect Dis Ther; 2023 Sep; 12(9):2321-2335. PubMed ID: 37751019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.
    Millham LRI; Scott JA; Sax PE; Shebl FM; Reddy KP; Losina E; Walensky RP; Freedberg KA
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):148-156. PubMed ID: 31929403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.
    Ogbuagu O; Molina JM; Chetchotisakd P; Ramgopal MN; Sanchez W; Brunetta J; Castelli F; Crofoot GE; Hung CC; Ronot-Bregigeon S; Margot NA; Wang H; Dvory-Sobol H; Rhee MS; Segal-Maurer S
    Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39206943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fostemsavir for the treatment of HIV.
    Seval N; Frank C; Kozal M
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):961-966. PubMed ID: 33331202
    [No Abstract]   [Full Text] [Related]  

  • 18. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
    Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
    Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating fostemsavir as a therapeutic option for patients with HIV.
    Berruti M; Pincino R; Taramasso L; Di Biagio A
    Expert Opin Pharmacother; 2021 Aug; 22(12):1539-1545. PubMed ID: 34125644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenacapavir (Sunlenca) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2023 May; 65(1675):68-70. PubMed ID: 37155250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.